U.S. FDA Grants Priority Review of New Drug Application for Gilead's Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir Life Science Investing
Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results Life Science Investing
Pfizer's ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma Pharmaceutical Investing
Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets Life Science Investing
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE Life Science Investing
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel Life Science Investing
AbbVie Submits Application to FDA for Upadacitinib for Adults and Adolescents with Severe Alopecia Areata Pharmaceutical Investing
RINVOQ® Demonstrated Superiority Versus HUMIRA® for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF inhibitor Pharmaceutical Investing
EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie Pharmaceutical Investing
